Skip to main contentSkip to main content
Updating results

Clinical Trials

  • Updated

WASHINGTON (AP) — Medicare said Tuesday it will limit coverage of a $28,000-a-year Alzheimer’s drug whose benefits have been widely questioned, a major development in the nation’s tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.

Get up-to-the-minute news sent straight to your device.


Breaking News